Drug Discovery & Development
NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe, according to leaders from the U.S. National Institutes of Health (NIH) and the Fred Hutchinson Cancer Research Center. They discussed how in Science on May 11.  Discuss
Researchers call for rapid drug repurposing to fight COVID-19
Filling the therapeutic gap for coronavirus treatments with existing drugs approved for other uses could greatly benefit patients around the world. Researchers from the University of Kentucky urged the scientific community to quickly identify drugs that may be repurposed in the fight against COVID-19 in an opinion piece published May 8 in Science.  Discuss
COVID-19: A double-edged sword for the pharma industry
The COVID-19 pandemic is causing major disruptions to pharmaceutical R&D activities, despite the pressing need for treatments and diagnostics for the novel coronavirus. In a new article, Ivan Gandayuwana of Strategic Directions International examines the multiple impacts COVID-19 is having on pharma.  Discuss
COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19 vaccine candidates, five of which have already entered clinical trials.  Discuss
Funding floodgates open for COVID-19 research
The impacts of the COVID-19 pandemic are being felt around the world. Researchers are working at a record-setting pace to understand the novel coronavirus and develop and test therapies. As seen by recent funding announcements, mitigating the economic effects of this crisis is a top priority for the global community.  Discuss
Controversy hits Gilead over orphan status for COVID-19 drug
Gilead Sciences has rescinded its request for orphan drug status for an experimental drug for treating COVID-19 just two days after getting approval from the U.S. Food and Drug Administration. The company had been hit with criticism that the approval would block other COVID-19 drugs from reaching the market.  Discuss
3 reasons the coronavirus outbreak has been so severe
WASHINGTON, DC - Why has the current outbreak of coronavirus been so severe compared with past epidemics of viral respiratory diseases? It has to do with unique characteristics of the coronavirus itself, according to a speaker at a February 26 congressional briefing.  Discuss
Large-scale study finds genetic variant responsible for detrimental immune response to common anti-inflammatory drugs
Researchers in the UK seek to understand why commonly used medication fails to treat Chron's disease by identifying a new genetic marker. The research published in Gastroenterology on October 7, identified a genetic variation that decreases the efficiency of anti-tumor necrosis factor (anti-TNF) drugs.
Repurposed drug shows potential to slow neurodegeneration in Parkinson's disease patients
Collaborative research from the University of Iowa and researchers in China and Spain, show evidence that a current drug used to treat prostate cancer may improve Parkinson's disease (PD) symptoms by slow neurodegeneration. The results from experimental models and clinical database analysis were published on September 16, in the Journal of Clinical Investigation.  Discuss
Germline genetic testing in breast cancer patients may lead to increased therapy options
Genetic testing for metastatic breast cancer patients may play a key role in identifying additional patients with increased risk and their response to targeted therapies.  Discuss
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter